Dr. Manojkumar Bupathi, MD, MS
Claim this profileRocky Mountain Cancer Center
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
10 reported clinical trials
22 drugs studied
Area of expertise
1Ovarian Cancer
Stage IV
Stage III
BRCA1
2Fallopian Tube Cancer
Stage IV
Stage III
BRCA1
Affiliated Hospitals
Clinical Trials Manojkumar Bupathi, MD, MS is currently running
HC-7366 + Belzutifan
for Kidney Cancer
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.
Recruiting1 award Phase 1
ART0380
for Advanced Cancer
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
Recruiting1 award Phase 1 & 214 criteria
More about Manojkumar Bupathi, MD, MS
Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Manojkumar Bupathi, MD, MS has experience with
- Carboplatin
- Trastuzumab
- Abemaciclib
- Paclitaxel
- Oregovomab
- Cisplatin
Breakdown of trials Manojkumar Bupathi, MD, MS has run
Ovarian Cancer
Fallopian Tube Cancer
Pancreatic Cancer
Peritoneal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Manojkumar Bupathi, MD, MS specialize in?
Manojkumar Bupathi, MD, MS focuses on Ovarian Cancer and Fallopian Tube Cancer. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are Stage III.
Is Manojkumar Bupathi, MD, MS currently recruiting for clinical trials?
Yes, Manojkumar Bupathi, MD, MS is currently recruiting for 2 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Manojkumar Bupathi, MD, MS has studied deeply?
Yes, Manojkumar Bupathi, MD, MS has studied treatments such as Carboplatin, Trastuzumab, Abemaciclib.
What is the best way to schedule an appointment with Manojkumar Bupathi, MD, MS?
Apply for one of the trials that Manojkumar Bupathi, MD, MS is conducting.
What is the office address of Manojkumar Bupathi, MD, MS?
The office of Manojkumar Bupathi, MD, MS is located at: Rocky Mountain Cancer Center, Aurora, Colorado 80012 United States. This is the address for their practice at the Rocky Mountain Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.